A promising strategy for the treatment of high metastatic breast cancers, including HER-2-positive and triple-negative (TNBC) breast cancers, may be targeting breast cancer stem cells (BCSCs) [124,140]. This evidence concerns the gene ERBB2 and breast cancer.